

RECEIVED
CENTRAL FAX CENTER

FEB 16 2006

FAX TRANSMISSION**DATE:** February 16, 2006**PTO IDENTIFIER:** Application Number 10/737290
Patent Number**Inventor:** Bowdish et al.**MESSAGE TO:** US Patent and Trademark Office**FAX NUMBER:** (571) 273-8300**FROM:** ROPES & GRAY LLP

Jennifer Holmes

PHONE: (617) 951-7933**Attorney Dkt. #:** ALEX-P04-054**PAGES (Including Cover Sheet):** 8**CONTENTS:** Information Disclosure Statement (2 pages)
IDS (Citation) by Applicant (4 pages)
Certificate of Transmission (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 951-7796 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

ROPES & GRAY LLPOne International Place, Boston, Massachusetts 02110-2624
Telephone: (617) 951-7000 **Facsimile:** (617) 951-7050

FEB 16 2006

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: 2-16-06 Signature: Maura A. Gallagher
(Maura A. Gallagher)

Docket No.: ALEX-P04-054
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bowdish et al.

Application No.: 10/737290

Confirmation No.: 6650

Filed: December 15, 2003

Art Unit: 1643

For: RATIONALLY DESIGNED ANTIBODIES

Examiner: P. K. Tungaturthi

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Copies of the references on the PTO/SB/08 are not supplied because they were previously cited by, or submitted to, the Office in prior application numbers 10/307724, filed December 2, 2002, or 10/006593, filed December 5, 2001, and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

Application No.: 10/737290

Docket No.: ALEX-P04-054

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ALEX-P04-054.

Dated: February 16, 2006

Respectfully submitted,

By 
Jennifer Holmes, Ph.D., J.D.

Registration No.: 46,778

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

RECEIVED
CENTRAL FAX CENTER

FEB 16 2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/737290	
			Filing Date	December 15, 2003	
			First Named Inventor	Katherine S. Bowdish	
			Art Unit	1643	
			Examiner Name	P.K. Tungaturthi	
			Attorney Docket Number	ALEX-P04-054	
Sheet	1	of	4		

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-4,642,334	02-10-1987	Moore et al.	
	AB	US-4,783,330	11-08-1988	Furie et al.	
	AC	US-4,816,397	03-28-1989	Boss et al.	
	AD	US-5,116,964	05-26-1992	Capon et al.	
	AE	US-5,219,996	06-05-1993	Bodmer et al.	
	AF	US-5,223,409	06-29-1993	Ladner et al.	
	AG	US-5,260,417	11-09-1993	Grant et al.	
	AH	US-5,428,130	06-27-1995	Capon et al.	
	AI	US-5,571,698	11-05-1996	Ladner et al.	
	AJ	US-5,593,666	01-14-1997	McDonald	
	AK	US-5,598,435	12-16-1997	Robinson et al.	
	AL	US-5,750,373	05-12-1998	Garrard et al.	
	AM	US-5,773,569	06-30-1998	Wrighton et al.	
	AN	US-5,837,500	11-17-1998	Ladner et al.	
	AO	US-5,869,451	02-09-1999	Dower et al.	
	AP	US-5,874,253	02-23-1999	Tsujimoto et al.	
	AQ	US-5,876,961	03-02-1999	Crowe et al.	
	AR	US-5,919,758	07-06-1999	Sytkowski	
	AS	US-5,932,546	08-03-1999	Barrett et al.	
	AT	US-5,965,405	10-12-1999	Winter et al.	
	AU	US-5,969,108	10-19-1999	McCafferty et al.	
	AV	US-6,008,023	12-28-1999	Opfer et al.	
	AW	US-6,040,136	03-21-2000	Garrard et al.	
	AX	US-6,172,197	01-09-2001	McCafferty et al.	
	AY	US-6,660,843	12-09-1993	Felge et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-0024782	05-04-2000			
	BB	WO-0061637	10-19-2000			
	BC	WO-02078612	10-10-2002			
	BD	WO-9418221	08-18-1994			
	BE	WO-9511317	04-27-1995			
	BF	WO-9529690	11-09-1995			
	BG	WO-9640189	12-19-1996			
	BH	WO-9640750	12-19-1996			
	BI	WO-9910494	03-04-1999			
	BJ	WO-9925378	05-27-1999			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.96(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
-----------------------	--------------------

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/737290	
			Filing Date	December 15, 2003	
			First Named Inventor	Katherine S. Bowdish	
			Art Unit	1643	
			Examiner Name	P.K. Tungaturthi	
Sheet	2	of	4	Attorney Docket Number	ALEX-P04-054

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Alfthan, Kaija, et. al. "Properties of a single-chain antibody containing different linker peptides". 1995. Protein Engineering Vol. 8, No. 7, pp. 725-731.	
	CB	Barbas III, Carlos F., et. al. "Assembly of combinatorial antibody libraries on phage surfaces: The gene III site". September 1991. Proc. Natl. Acad. Sci. USA Biochemistry. Vol. 88, pp. 7978-7982.	
	CC	Barbas, Shana M., et. al. "Human autoantibody recognition of DNA". March 1995. Proc. Natl. Acad. Sci. USA. Vol 92, pp. 2529-2533.	
	CD	Barbas, Shana M., et. al. "Recognition of DNA by Synthetic Antibodies". November 10, 1993. J. AM. Chem. Soc., Vol. 116, No. 5 pp. 2161-2162.	
	CE	Better, Marc, et. al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab') ₂ ". January 1993, Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 457-461. Immunology.	
	CF	Burton, Dennis R., et. al. "Human Antibodies from Combinatorial Libraries". 1994, Advances in Immunology, Vol. 57, pp. 191-280.	
	CG	Carlson, John R., et al., "Molecular Tools for Inactivating a Yeast Enzyme In Vivo". June 1988, Molecular and Cellular Biology, Vol. 8, No. 6 pp. 2647-2650.	
	CH	Carter, Paul, et. al. "High level Escherichia coli expression and production of a bivalent humanized antibody fragment" Bio/Technology Vol. 10 pp. 163-167.	
	CI	Chaiken I M et al., Identifying Structure-Function Relationships in Four-Helix Bundle Cytokines: Towards De Nova Mimetics Design, Trends in Biotechnology, Elsevier Publications, Cambridge, GB, Vol. 14, No. 10, October 1, 1996, pp 369-375.	
	CJ	Cook, Jeremy, Recombinant Antibodies Containing an Engineered B-Cell Epitope Capable of Eliciting Conformation-Specific Antibody Responses, Butterworth Heinemann, Vaccine, Vol. 13, No. 18, pp. 1770-1778, 1995, Elsevier Science Ltd.	
	CK	Cwirla, Steven E., et. al., "Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine", June 13, 1997, Science, Vol. 276 pp. 1696-1699.	
	CL	de Kruijff, John, et. al. "Leucine zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library". March 29, 1996. The J. of Biological Chemistry, Vol. 271, No. 13, pp. 7630-7634.	
	CM	de Sauvage, Frederic J., et. al. "Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand". June 1994, Nature, Vol. 369, pp. 533-538.	
	CN	DeBernardi, Maria A., et al., "Single cell Ca ²⁺ /cAMP cross-talk monitored by simultaneous Ca ²⁺ /cAMP fluorescence ratio imaging". May 1996, Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 4577-4582, Cell Biology.	
	CO	Deng, Su-jun, et. al. "Synthetic Antibody Gene Libraries for In Vitro Affinity Maturation". 1995, Methods in Molecular Biolog, Vol. 51: Antibody Engineering Protocols. pp. 329-342.	
	CP	Deng, B. et al. "An Agonist Murine Monoclonal Antibody To The Human C-MPL Receptor Stimulates In Vitro MegaKaryocytopoiesis," Abstract No. XP-002095741 (260)	
	CQ	Drachman, Jonathan G., et. al. "Thrombopoietin Signal Transduction Requires Functional JAK2, Not TYK2. May 7, 1999, The J. of Biological Chemistry, Vol. 274, No. 19, pp. 13480-13484.	
	CR	Eaves, C.J., "Assays of Hemopoietic Progenitor Cells". Williams Hematology. 5th Edition, Chapter L4, pp. L22-L26.	
	CS	European Search Report for EP04077554 dated September 21, 2005	
	CT	Gallinari, Paola, et. al. "Localization of a 34-Amino-Acid Segment Implicated in Dimerization of	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/737290
		Filing Date	December 15, 2003
		First Named Inventor	Katherine S. Bowdish
		Art Unit	1643
		Examiner Name	P.K. Tungaturthi
Sheet	3	of	4
		Attorney Docket Number	ALEX-P04-054

		the Herpes Simplex Virus Type 1 ICP4 Ploypeptide by a Dimerization Trap". June 1994, J. of Virology, Vol. 68, No. 6, pp. 3809-3820.	
CU		Hawkins, Robert E., et. al. "Selection of Phage Antibodies by Binding Affinity". April, 1992. J. Mol. Biol. 226, pp. 889-896.	
CV		Hayden M S ET AL, Antibody Engineering, current Opinion in Immunology, Current Biology Ltd, XX, Vol. 9, No. 2, April 1997, pp. 201-212	
CW		Healy, Judith M., et. al. "Peptide Ligands for Integrin avb3 Selected from Random Phage Display Libraries". January 13, 1995 Biochemistry Vol. 34, No. 12, 1995. pp. 3948-3955.	
CX		Helms, Larry, R., et. al., "Destabilizing loop swaps in the CDRs of an immunoglobulin VL domain," Protein Science, 4:2073-2081 (1995).	
CY		Hiatt, Andrew, et. al., "Production of antibodies in transgenic plants". November 2, 1989, Nature, Vol. 342, pp 76-78.	
CZ		Hiltunen, Timo, et. al. "Assembly of Humanized Antibody Genes from Synthetic Oligonucleotides Using a Single-Round PCR". March 10, 1994. BioTechniques Vol. 17, No. 2.	
CA1		Holliger, Philipp, et. al. "Engineering bispecific antibodies". 1993, Biotechnology, Vol. 4, pp. 446-449.	
CB1		Ihle, James N., et. al., "Signaling Through the Hematopoietic Cytokine Receptors". (1995), Annu. Rev. Immunology, Vol. 13, pp. 369-398.	
CC1		Jagerschmidt, Alexandre, Human Trombopietin Structure-Function Relationships: Identification of Functionally Important Residues, Biochem. J. (1998) 333, 729-734.	
CD1		Kamura, Takumi, Characterization of Human Thrombopoietin Gene Promoter, The Journal of Biological Chemistry, 1997 by The American Society for Biochemistry and Molecular Biology, Inc., Vol. 272, No. 17, Issue of April 25, pp. 11361-11368, 1997	
CE1		Kim, Baek, et. al. "Dimerization of a Specific DNA-Binding Protein on the DNA". January 1992, Science, Vol. 255, pp. 203-206.	
CF1		Kini, R. Manjunatha, et. al. "A novel approach to the design of potent bioactive peptides by incorporation of proline brackets: antiplatelet effects of Arg-Gly-Asp peptides" (1995) FEBS Letters, pp. 15-17.	
CG1		Kitamura, Toshio, et. al. "Establishment and Characterization of a Unique Human Cell Line That Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin" February 28, 1989, J. of Cellular Physiology Vol. 140 pp. 323-334.	
CH1		Kitamura, Toshio, et. al. "Identification and Analysis of Human Erythropoietin Receptors on a Factor-Dependent Cell Line, TF-1". February 1989, Blood. Vol. 73, No.2, pp. 375-380.	
CI1		Kitamura, Toshio, et. al. "IL-1 up-regulates the expression of cytokine receptors on a factor-dependent human hemopoietic cell line, TF-1". (1991) International Immunology, Vol. 3, No. 6 pp. 571-577.	
CJ1		Klose, Karl E., et. al. "The major Dimerization Determinants of the Nitrogen Regulatory Protein NTRC from Enteric Bacteria Lie in Its Carboxy-terminal Domain". (1994) J. Mol. Biol. Vol. 241, pp. 233-245.	
CK1		Knappik, Achim, et. al. "Fully Sythetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDR's Randomized with Trinucleotides". J. Mol. Biol. (2000). 296, pp. 57-86.	
CL1		Koivunent, Erkki, et. al. "Phage Libraries Displaying Cyclic peptides with Different Ring Sizes: Ligand Specificities of the RDG-Directed Integrins" BIO/TECHNOLOGY Vol. 13 March 1995 pp. 265-270.	
CM1		Koivunent, Erkki, et. al. "Selection of Peptides Binding to the 5b1 Integrin from Phage Display Library". September 25, 1993. The J. of Biological Chemistry. Vol. 268, No. 27, pp. 20205-20210.	
CN1		Kortt, Alexander A., et. al. "Recombinant anti-sialidase single-chain variable fragment antibody". 1994. Eur. J. Biochem. 221, pp. 151-157.	
CO1		Kostelny, Sheri A., et. al. "Formation of a Bispecific Antibody By The Use Of Leucine Zippers".	
Examiner	000000	Date Considered	

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/737290
		Filing Date	December 15, 2003
		First Named Inventor	Katherine S. Bowdish
		Art Unit	1643
		Examiner Name	P.K. Tungaturthi
Sheet	4	of	4
		Attorney Docket Number	ALEX-P04-054

		March 1, 1992, The J. of Immunology, Vol. 148, No. 5, pp. 1547-1553.	
CP1		Kourmenis, Iphigenia Leonidou, et al., "Modulating pharmacokinetics of an anti-interleukin-8F(ab') ₂ by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol. 198, pp. 83-95.	
CQ1		Kunel, Thomas A., "Rapid and efficient site-specific mutagenesis without phenotypic selection". January 1985. Proc. Natl. Acad. Sci. US Vol. 82, pp. 488-492.	
CR1		Lang, Irene M., et al. "Purification of Storage Granule Protein-23". November 22, 1996. The J. of Biological Chemistry. Vol. 271, No. 47, pp. 30126-30135.	
CS1		Lee, L. Stanford, et al. "Prolonged Circulating Lives of Single-Chain Fv Proteins Conjugation Chemistries and Compounds". (1999) Bioconjugate Chemistry, Vol. 10, No. 6, pp 973-981.	
CT1		MacBeath, Gavin, et al., "Redesigning Enzyme Topology by Directed Evolution". March 20, 1998, Science. Vol. 279; pp. 1958-1961.	
CU1		MacBeath, Gavin, et al. "A Small, Thermosable, and Monofunctional Chorismate Mutase from the Archeon Methanococcus jannaschii". (1998) Biochemistry Vol. Vol. 37, pp. 10062-10073.	
CV1		Monfardini, C. et al. "Recombinant Antibodies in Bioactive Peptide Design," J. Biochem. 270(12):6628-6638 (1995)	
CW1		Mosmann, Tim, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays". (1983) J. of Immunological Methods"> Vol. 63, pp. 5563.	
CX1		Pack, Peter, et al. "Miniantibodies: Use of Amphipathic Helices To Produce Functional, Flexibly Linked Dimeric Fv Fragments with High Activity in Escherichia coli". February 18, 1992, Biochemistry, Vol. 31, No. 6, pp. 1579-1584.	
CY1		Parhami-Seren B. ET AL, Selection of High Affinity P-Azophenylarsonate Fabs From Heavy-Chain CDR2 Insertion Libraries, Journal of Immunological Methods, Elsevier Science Publishers B.V., Amsterdam, NL, Vol. 259, No. 1-2, January 1, 2002	
CZ1		Raines, Elaine W., et al. "Purification of Human Platelet-Derived Growth Factor". (1985) Methods in Enzymology, Vol. 109, pp. 749-773.	
CA2		Shi, Xu-Bao, et al. "Rapid PCR Construction of a Gene Containing Lym-1 Antibody Variable Regions". August, 1993. PCR Methods-And-Applications Vol. 3, No.1. pp. 46-53.	
CB2		Siegel, Don L., et al. "Isolation of cell surface-specific human monoclonal antibodies using phage display and magnetically-activated cell sorting: applications in Immunohematology". 1997, J. of Immunological Methods, 206 pp. 73-85.	
CC2		Spaeny-Dekking, Liesbeth, et al. "Gin Invertase of Bacteriophage Mu Is a Dimer in Solution, with the omain for Dimerization in the N-Terminal Part of the Protein". (1995) Biochemistry Vol. 34, pp. 1779-1786.	
CD2		Trill, John J., et al., "Production of monoclonal antibodies in COS and CHO cells". (1995), Current Opinion In Biotechnology, Vol. 6 pp. 553-560.	
CE2		van Heecheren, William J., et al. "Role of the conserved leucines in the leucine zipper dimerization motif of yeast GCN4". June 12, 1992, Nucleic Acids Research, Vol. 20. No. 14, pp. 3721-3724.	
CF2		Witthuhn, Bruce A., et al. "JAK2 Associates with the Erythropoietin Receptor and Is Tyrosine Phosphorylated and Activated following Stimulation with Erythropoien". July 30, 1993, Cell, Vol. 74, pp. 227-236.	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/737290

Attorney Docket No.: ALEX-P04-054

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on February 16, 2006
Date

Maura A. Gallagher
Signature

Maura A. Gallagher

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Information Disclosure Statement (2 pages)
IDS (Citation) by Applicant (4 pages)